Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (91-100 of 181) with videos related to

Pageof 19
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|December 21, 2013
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosisJames Foran, Farhad Ravandi, William Wierda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinFarhad Ravandi, Eli Estey, Dan Jones, et al.
Blood|August 16, 2008
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Jeffrey L Jorgensen, et al.
Cancer|December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimensWilliam Wierda, Susan O'brien, Stefan Faderl, et al.
American Journal of Hematology|October 14, 2017
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitorsAhmad Alhuraiji, Hagop Kantarjian, Prajwal Boddu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaMichael J Keating, Susan O'Brien, Maher Albitar, et al.
Molecular Cancer Research : MCR|May 20, 2014
STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosisPing Li, David Harris, Zhiming Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsFarhad Ravandi, Ahmed Aribi, Susan O'Brien, et al.
American Journal of Hematology|April 22, 2011
Prediction model for mortality after intracranial hemorrhage in patients with leukemiaFarshid Dayyani, Sarah Schellhorn Mougalian, Kiran Naqvi, et al.
Molecular Cancer Research : MCR|January 29, 2017
Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 ComplexUri Rozovski, David M Harris, Ping Li, et al.
Pageof 19

Showing results (91-100 of 181) with videos related to

Sort By:
Pageof 19
Clinical Lymphoma, Myeloma & Leukemia|December 21, 2013
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosisJames Foran, Farhad Ravandi, William Wierda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinFarhad Ravandi, Eli Estey, Dan Jones, et al.
Blood|August 16, 2008
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Jeffrey L Jorgensen, et al.
Cancer|December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimensWilliam Wierda, Susan O'brien, Stefan Faderl, et al.
American Journal of Hematology|October 14, 2017
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitorsAhmad Alhuraiji, Hagop Kantarjian, Prajwal Boddu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaMichael J Keating, Susan O'Brien, Maher Albitar, et al.
Molecular Cancer Research : MCR|May 20, 2014
STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosisPing Li, David Harris, Zhiming Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsFarhad Ravandi, Ahmed Aribi, Susan O'Brien, et al.
American Journal of Hematology|April 22, 2011
Prediction model for mortality after intracranial hemorrhage in patients with leukemiaFarshid Dayyani, Sarah Schellhorn Mougalian, Kiran Naqvi, et al.
Molecular Cancer Research : MCR|January 29, 2017
Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 ComplexUri Rozovski, David M Harris, Ping Li, et al.
Pageof 19